Cancers, Vol. 16, Pages 968: Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma

Cancers, Vol. 16, Pages 968: Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma Cancers doi: 10.3390/cancers16050968 Authors: Agata Marjańska Katarzyna Pawińska-Wąsikowska Aleksandra Wieczorek Monika Drogosiewicz Bożenna Dembowska-Bagińska Katarzyna Bobeff Wojciech Młynarski Katarzyna Adamczewska-Wawrzynowicz Jacek Wachowiak Małgorzata A. Krawczyk Ninela Irga-Jaworska Jadwiga Węcławek-Tompol Krzysztof Kałwak Małgorzata Sawicka-Żukowska Maryna Krawczuk-Rybak Anna Raciborska Agnieszka Mizia-Malarz Agata Sobocińska-Mirska Paweł Łaguna Walentyna Balwierz Jan Styczyński Background/aim: The role of immune checkpoint inhibitors (ICIs; anti-PD1) in the treatment of childhood cancers is still evolving. The aim of this nationwide retrospective study was to assess the safety and effectiveness of ICIs used in a group of 42 patients, with a median age of 13.6 years, with various types of advanced malignancies treated in pediatric oncology centers in Poland between 2015 and 2023. Results: The indications for treatment with anti-PD1 were as follows: Hodgkin lymphoma (11); malignant skin melanoma (9); neuroblastoma (8); and other malignancies (14). At the end of follow-up, complete remission (CR) was observed in 37.7% (15/42) of children and disease stabilization in 9.5% (4/42), with a mean survival 3.6 (95% CI = 2.6–4.6) years. The best surv...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research